These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16804389)

  • 21. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
    Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
    J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
    Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
    Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
    Bitton A
    Semin Gastrointest Dis; 2001 Oct; 12(4):263-74. PubMed ID: 11726080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ulcerative colitis in Thailand: a clinical study and long term follow-up.
    Pongprasobchai S; Manatsathit S; Leelakusolvong S; Sattawatthamrong Y; Boonyapisit S
    J Med Assoc Thai; 2001 Sep; 84(9):1281-8. PubMed ID: 11800302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?].
    Braucci S; Trappolini F; Angrisani L; Luberti E; Clarice A; Proietta M; Pisani D; Trappolini M
    Clin Ter; 2007; 158(1):27-30. PubMed ID: 17405657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
    Regueiro M; Loftus EV; Steinhart AH; Cohen RD
    Inflamm Bowel Dis; 2006 Oct; 12(10):979-94. PubMed ID: 17012969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release mesalamine granules for ulcerative colitis.
    Love BL; Miller AD
    Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
    Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
    Kruis W; Jonaitis L; Pokrotnieks J; Mikhailova TL; Horynski M; Bátovský M; Lozynsky YS; Zakharash Y; Rácz I; Kull K; Vcev A; Faszczyk M; Dilger K; Greinwald R; Mueller R;
    Aliment Pharmacol Ther; 2011 Feb; 33(3):313-22. PubMed ID: 21138455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
    Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
    Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
    Khan N; Abbas AM; Koleva YN; Bazzano LA
    Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.